Your cart is empty
Browse transcripts and add items to get started.
UnitedHealth Group reported Q1 2026 diluted EPS of $6.90, up from $6.85 a year ago, on revenues of $111.7 billion, a 2% year-over-year increase driven by UnitedHealthcare pricing and Optum Rx growth. Operating earnings of $9.0 billion remained broadly stable despite elevated restructuring costs and continued membership contraction across Medicare Advantage and Medicaid.
Performance Highlights
UnitedHealth Group posted Q1 2026 total revenues of $111.7 billion, up 2% year-over-year, with diluted EPS of $6.90 versus $6.85 in Q1 2025, representing a modest beat against consensus. Earnings from operations came in at $9.0 billion, marginally below the prior-year $9.1 billion, as restructuring charges and elevated operating costs partially offset revenue growth. The medical care ratio improved 90 basis points to 83.9%, aided by $1.05 billion of favorable prior-year reserve development tied to a milder-than-expected respiratory illness season and affordability initiatives. Operating cash flow of $8.9 billion was robust, nearly doubling the prior-year Q1 figure of $5.5 billion, reflecting improved working capital dynamics.
UnitedHealthcare was the primary earnings driver, with segment operating income rising 9% to $5.7 billion and operating margin expanding 40 basis points to 6.6%, supported by pricing discipline across commercial and Medicare lines. Optum collectively faced headwinds, with segment earnings from operations declining 15% to $3.3 billion; Optum Health fell 19% to $1.1 billion as value-based care volume contracted, Optum Insight dropped 17% to $963 million partly due to a $400 million United Health Foundation contribution, and Optum Rx slipped 10% to $1.2 billion on thinner margins.
Management Outlook and Forward Catalysts
Management signaled that Medicare Advantage membership contraction and Medicaid rate inadequacy will persist through 2026, with benefit design adjustments and selective market exits the primary tools to stabilise margins. The 2027 Medicare Advantage Final Rate Notice moved closer to industry medical cost trend but remains below it, suggesting continued structural rate pressure that management intends to offset through cost management, network adjustments and county-level plan participation decisions.
The central investor debate heading into Q2 2026 centres on whether the improvement in the medical care ratio is durable or a function of one-time reserve releases, and whether Optum's earnings recovery can offset ongoing UnitedHealthcare membership erosion across Medicare Advantage, Medicaid and commercial risk. Bulls will focus on the strong cash generation and pricing momentum; bears will watch membership trends, IRS transfer-pricing exposure and the trajectory of Medicaid rate resets.
Adjusted EPS vs. consensus breakdown — primary performance driver, segment revenue contribution, and gross margin trajectory relative to prior guidance...
Segment-by-segment revenue analysis, margin profile, and management commentary on demand trajectory vs. consensus range expectations...
Forward guidance implications for the sector, supply chain read-throughs, and investment implications for the broader competitive landscape...
